Document is current
Any future updates will be listed below
-
Authors
Shao, Wenwei
Pei, Xiaolei
Cui, Caibin
Askew, Charles
Dobbins, Amanda
Chen, Xiaojing
Abajas, Yasmina L.
Gerber, David A. http://orcid.org/0000-0002-7972-5228
Samulski, R. Jude
Nichols, Timothy C.
Li, Chengwen
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (P01HL112761, P01HL112761, R01HL125749, R01HL144661)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI117408, R01AI117408)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
- License Information
-
More Information
Article History
Received: 23 April 2019
Revised: 19 September 2019
Accepted: 19 September 2019
First Online: 30 September 2019
Compliance with ethical standards
:
: RJS is the founder and a shareholder at Asklepios BioPharmaceutical and Bamboo Therapeutics, Inc. He holds patents that have been licensed by UNC to Asklepios Biopharmaceutical, for which he receives royalties. He has consulted for Baxter Healthcare and has received payment for speaking. CL is a cofounder of Bedrock Therapeutics, Inc. He has licensed patents by UNC and has received royalties from Bedrock Therapeutics and Asklepios Biopharmaceutical. The other authors declare that they have no conflict of interest.
